Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Behavioral, psychological, and clinical outcomes of Arabic-speaking people with type 2 diabetes during COVID-19 pandemic

Hamzah Alzubaidi a,b,*, Khadija Hafidh c, Ward Saidawi b, Amna M. Othman a, Mahta M. Khakpour a, Malaka M. Zoghbor a,d,1, Eman Abu-Gharbieh b,c,2, Karem H. Alzoubi a, Jonathan E. Shaw f

a College of Pharmacy, University of Sharjah, University City Road, University City, PO Box 27272, Sharjah, United Arab Emirates
b Sharjah Institute for Medical Research, University of Sharjah, University City Road - University City, PO Box 27272, Sharjah, United Arab Emirates
c Rashid Hospital, Dubai Health Authority UAE, Dubai Medical College, United Arab Emirates
d Pharmacist, Fakeeh University Hospital, Dubai Silicon Oasis, Dubai, United Arab Emirates
e Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
f Clinical and Population Health, Baker Institute, Baker Heart and Diabetes Institute, Level 4, 99 Commercial Road, PO Box 6492, Melbourne, VIC 3004, Australia

ARTICLE INFO

Keywords:
COVID-19
Diabetes mellitus, type 2
United Arab Emirates
Delivery of health care
Self-management
Psychological distress

ABSTRACT

Aims: Assess self-care activities, health behaviors, self-efficacy, diabetes distress, challenges, and changes in diabetes treatment and clinical parameters among Arabic-speaking people with T2DM during the COVID-19 pandemic.

Methods: A cross-sectional study was conducted at a tertiary hospital in the United Arab Emirates. The study instrument collected self-reported data using validated tools about health behaviors, self-efficacy, and diabetes distress, and challenges in accessing and using healthcare services during the pandemic and documented clinical data and treatment before and during the pandemic from medical records.

Results: 206 patients participated with a mean age of 58.7 years and 15.7 years since diabetes diagnosis. Non-adherence to healthful eating and exercise was reported by 38.3% and 73.7%, respectively. Exercise was the self-care activity that decreased the most (36.8%). Most participants had low diabetes distress (85.9%). There were no significant differences in clinical parameters before and during the pandemic, and diabetes treatment was unchanged for 72.8% of participants. Having two or more challenges with accessing and using diabetes healthcare services was significantly associated with decreased adherence to healthy eating (p = 0.025) and exercise (p = 0.003).

Conclusions: Arabic-speaking people with T2DM appeared to maintain relatively similar self-care levels, except exercise, with no deterioration in clinical parameters compared to pre-pandemic.

1. Introduction

The 2019 coronavirus pandemic (COVID-19) continues to cause substantial morbidity and mortality globally [1]. Several factors are associated with worse COVID-19 health outcomes, including age and comorbidities, particularly diabetes and chronic lung disease [2]. There is a bidirectional relationship between COVID-19 and diabetes, where diabetes is associated with increased COVID-19 severity and mortality [3], and new-onset diabetes and severe metabolic complications of pre-existing diabetes have been reported in patients with COVID-19 [3]. A recent systematic review and meta-analysis of studies from Asia, Europe, and the United States (US) that included nearly 79,000 adults found that COVID-19 patients with diabetes had a two-fold higher risk of intensive care admission and nearly three-fold increased risk of...
in-hospital mortality [4]. Poor glycemic control seems to be emerging as a contributory factor to COVID-19 mortality outcomes among those with pre-existing diabetes. A multi-center study in China showed that the mortality rate among patients with hyperglycemia was 11% compared to 1.1% in well-controlled patients [5]. Another study revealed that glycemic stability corresponded with better outcomes in reducing the risk of mortality from the infection [6].

Even under ‘normal’ circumstances, diabetes can negatively affect the quality of life and mental health [7]. People with diabetes are known to have an increased prevalence of depression, anxiety, and stress compared to the general population [8]. Recently, an emphasis has been placed on understanding self-management practices and the broader psychosocial aspects in people with diabetes during the pandemic. Recent studies found a high prevalence of diabetes-specific worries related to COVID-19 [9,10]. These worries included fear of being overly affected by the virus, the perception that people with diabetes were at high risk, and the inability to manage diabetes if infected [9,10]. Similar findings were observed in a study in the Arabian Gulf region where a remarkably high prevalence of depression and anxiety symptoms were apparent particularly among subgroups of people with diabetes during the pandemic [11]. Managing diabetes and performing daily self-care activities are expected to be more challenging during the pandemic, particularly because of the impact on healthcare access [12]. Patients reported challenges like visiting physicians for regular appointments, refilling diabetes prescriptions, reduced physical activity, and dietary irregularity during the stay-at-home periods [13].

From a healthcare delivery perspective, a global survey that assessed the impact of COVID-19 on routine care for chronic diseases showed that diabetes care was the most severely affected [12]. Several factors, which were necessary to halt the spread of the COVID-19 pandemic, have impaired the provision of clinical care services and threatened the continuity of care for people with diabetes, particularly during the early phase of the pandemic. These included the contact precautions, closure of some healthcare services and sporting facilities, cancellation of routine medical appointments, and home confinement [14,15].

There is a paucity of data about how the COVID-19 pandemic affects people with diabetes in Arabic-speaking countries. However, studies prior to the pandemic have shown that Arabic-speaking people with diabetes have difficulties in achieving glycemic control (i.e., HbA1c <7.0% (53 mmol/mol)) owing to a range of beliefs, healthcare experiences, suboptimal medication adherence, and motivational barriers around self-care [16,17]. The United Arab Emirates (UAE) has one of the highest diabetes prevalence rates among adults in the world [18]. The government took several precautionary measures to limit spread of COVID-19 across the country, including social distancing, movement restrictions, and remote working. The COVID-19 outbreak in the UAE has resulted in more than 730,000 confirmed cases and exceeded 1200 deaths as of October 2021 [19]. This exploratory study aimed to assess the impact of the COVID-19 pandemic on self-care activities, health behaviors, self-efficacy, and diabetes distress using validated tools. Additionally, the challenges of people with diabetes during the pandemic, including those related to healthcare access were assessed. The second part of the instrument documented the clinical data and lab parameters from electronic medical records.

2.2. Participants

Between February and July 2021, potential participants were initially identified through the hospital database and were contacted by phone by trained research assistants. They explained the study objectives and procedures, and determined potential participants’ interest and eligibility. Arabic-speaking people with T2DM who 18 years of age or older and residing in the UAE were included in the study. Those diagnosed with type 2 diabetes less than one year ago, those with cancer or severe mental illness, and pregnant women were excluded. Verbal consent was obtained from interested and eligible participants before completing the survey.

2.3. Study instrument

A thorough literature search and discussions among the investigators and diabetes physicians informed the development of the study instrument. The self-report part of the instrument consisted of 28 items in six sections (A-F). Section A covered socio-demographic characteristics, including sex, education level, work status, and nationality. Participants’ knowledge about various aspects of diabetes self-care and the level of support received from health care providers and family were also assessed using a three-point scale (not sufficient, somewhat sufficient, and sufficient). Section B assessed diabetes self-efficacy using two validated items about participants’ confidence in taking diabetes medications and carrying out self-care activities. Section C evaluated the impact of the COVID-19 pandemic on health behaviors. The Summary of Diabetes Self-Care Activities was used to assess dietary habits, physical activity, self-monitoring of blood glucose ( SMBG), and smoking [20]. Participants were also asked to indicate the change in frequency of performing of these activities during the pandemic in comparison to a similar time before the pandemic. Sleeping habits before and during the COVID-19 pandemic were assessed using items adapted from the work of Grabia et al. [21]. Section E assessed diabetes distress during the last week using the two-item Diabetes Distress Scale (DDS-2) [22]. Participants indicated their responses on a six-point Likert scale, where 1 = not a problem and 6 = a very serious problem. Finally, section F assessed 10 potential challenges in accessing and using diabetes healthcare services during the COVID-19 pandemic. Participants rated the level of difficulty as challenging, somewhat challenging, or not challenging.

The clinical data collection tool had 12 items and was completed from electronic medical records to understand the pandemic’s association with clinical parameters and outcomes. Collected data included HbA1c level, lipid profile, serum creatinine, urinary albumin, body mass index, and diabetes treatment before and during the COVID-19 pandemic, years since diabetes diagnosis, comorbidities, and COVID-19 history. The period before the COVID-19 pandemic was defined as before 01 February 2020, and the time period during the pandemic was defined as on or after 01 February 2020. For each of these periods, the latest available clinical data were recorded.

The self-report survey was translated into Arabic by a certified translation service. The researchers then compared the Arabic translation to the original English survey, reaching a consensus on the translation of words, phrases, and items to ensure equivalence. The Arabic and English versions were then revised by academic physicians, endocrinologists, and diabetologists to establish content validity and the appropriateness of all items. Minor refinements in wording were made based on their recommendations. Next, the two versions of the survey were pilot tested with an internal medicine consultant, a diabetologist, and an endocrinologist to establish content validity and appropriateness.
of all items. Furthermore, they were pilot tested with people with diabetes to ensure the clarity of all items and to determine the time needed to complete the survey, which was found to be around 5 min.

2.4. Data analysis

Data were analyzed using the Statistical Package for Social Sciences (SPSS), Version 26. Continuous variables such as age, years since diabetes diagnosis, frequency of performing self-care activities, and clinical lab data were described using means and standard deviations (SD), and categorical variables such as sex, education level, challenges, and perceived knowledge were described using counts and frequencies. Participants were categorized into “adherent” if they reported engaging in recommended self-care activities on ≥ 4 days of the past week and “non-adherent” if they did not. Diabetes distress scores were determined by calculating mean scores for the two items, with scores of 2 or lower indicating low distress, scores greater than 2 but lower than 3.5 indicating moderate distress, and scores of 4 or above indicating high distress. Clinical lab data were tested using the Shapiro-Wilk and were found to be not normally distributed. Therefore, the Wilcoxon signed-rank test was used to identify differences in their levels before and during the COVID-19 pandemic. Finally, the Chi-squared test was used to identify associations between challenges with accessing and using diabetes healthcare services and knowledge about diabetes with changes in self-care activities during the pandemic. Participants who reported that two or more items were ‘challenging’ or ‘somewhat challenging’ were compared to those who reported fewer than two challenges, and participants who rated their knowledge on two or more items as ‘insufficient’ were compared to those who reported insufficient knowledge on fewer than two items. A p-value < 0.05 was considered statistically significant.

2.5. Ethical approvals

Ethical approvals were obtained from the Research & Graduate Studies Research Ethics Committee, University of XXXX (reference number REC-20-06-18-01) and the XXXX XXXX XXXX Ethics Committee (reference number DSREC-01/2021_03).

3. Results

A total of 206 participants completed the study survey with a response rate of 78%. Male:female ratio was 58:42%, and the mean age was 58.7 years (Table 1). Around one-third (32.7%) only had a high school diploma, while 34.6% did not have a high school diploma and 26.2% had a college/bachelor’s degree.

The mean duration of diabetes was 15.7 ± 8.0 years (Table 1). Almost all participants (96.5%) had documented comorbidities, the most prevalent being dyslipidemia (83.0%), hypertension (73.8%), and a history of heart attack (17.5%). Neuropathy was the most common diabetes complication (42.7%) followed by retinopathy (36.9%), and around one-third (34.0%) did not have documented complications. Nearly half the participants (49.5%) had a COVID-19 test documented in their electronic medical record, and of those, 12.7% had positive tests. Diabetes distress scores were determined by calculating mean scores for the two items, with scores of 2 or lower indicating low distress, scores greater than 2 but lower than 3.5 indicating moderate distress, and scores of 4 or above indicating high distress. Clinical lab data were tested using the Shapiro-Wilk and were found to be not normally distributed. Therefore, the Wilcoxon signed-rank test was used to identify differences in their levels before and during the COVID-19 pandemic. Finally, the Chi-squared test was used to identify associations between challenges with accessing and using diabetes healthcare services and knowledge about diabetes with changes in self-care activities during the pandemic. Participants who reported that two or more items were ‘challenging’ or ‘somewhat challenging’ were compared to those who reported fewer than two challenges, and participants who rated their knowledge on two or more items as ‘insufficient’ were compared to those who reported insufficient knowledge on fewer than two items. A p-value < 0.05 was considered statistically significant.

### Table 1

| Participant characteristics | n (%) |
|----------------------------|-------|
| Male sex                   | 119 (57.8) |
| Age (mean ± SD)            | 58.7 ± 11.2 |
| Nationality                |        |
| Emirati Arabs              | 158 (76.7) |
| Non-Emirati Arabs          | 48 (23.3) |
| Education Level            |        |
| Less than high school diploma | 70 (34.6) |
| High school diploma        | 66 (32.7) |
| College/Bachelor’s degree  | 53 (26.2) |
| Master’s degree            | 8 (4.0) |
| Other                      | 5 (2.5) |
| Employment status          |        |
| Employed                   | 78 (37.9) |
| Unemployed                 | 128 (62.1) |
| Years since diabetes diagnosis (mean ± SD) | 15.7 ± 8.0 |
| Comorbidities              |        |
| Dyslipidemia               | 171 (83.0) |
| High blood pressure        | 152 (73.8) |
| History of heart attack    | 36 (17.5) |
| Chronic kidney disease     | 29 (14.1) |
| Arthritis                  | 22 (10.7) |
| Others                     | 151 (73.3) |
| No co-morbidities          | 7 (3.5) |
| Diabetes Complications     |        |
| Neuropathy                 | 88 (42.7) |
| Retinopathy                | 76 (36.9) |
| Albuminuria                | 38 (18.4) |
| Amputation                 | 9 (4.4) |
| Others                     | 10 (4.9) |
| No complications           | 69 (34.0) |
| COVID-19 test result documented | 102 (49.5) |
| Diagnosed with COVID-19    | 13/102 (12.7) |
| Hospitalized due to COVID-19 | 10/13 (76.9) |

### Table 2a

| Self-care activities and health behaviors | n (%) |
|-----------------------------------------|-------|
| Healthful eating habits                  |       |
| Adherent                                | 127 (61.7) |
| Non-adherent                            | 79 (38.3) |
| Fruit and vegetable intake              |       |
| Adherent                                | 55 (26.7) |
| Non-adherent                            | 151 (73.3) |
| Avoiding eating high-fat foods          |       |
| Adherent                                | 160 (77.7) |
| Non-adherent                            | 46 (22.3) |
| At least 30 min of physical activity    |       |
| Adherent                                | 54 (26.3) |
| Non-adherent                            | 151 (73.7) |
| Specific exercise session               |       |
| Adherent                                | 34 (16.5) |
| Non-adherent                            | 172 (83.5) |
| Self-monitoring of blood glucose        |       |
| Adherent                                | 108 (52.4) |
| Non-adherent                            | 98 (47.6) |
| Foot care                               |       |
| Adherent                                | 109 (52.9) |
| Non-adherent                            | 96 (46.6) |
| Smoking                                 |       |
| Non-adherent                            | 96 (46.6) |
| Number of cigarettes per day (mean ± SD) | 17.2 ± 13.0 |
| Sedentary hours per day (mean ± SD)     | 7.8 ± 4.6 |
| Sleep duration at night before the pandemic |       |
| ≥8 h                                    | 82 (40.1) |
| 6–8 h                                   | 107 (51.9) |
| <6 h                                    | 73 (35.4) |
| Sleep duration at night during the pandemic |       |
| ≥8 h                                    | 29 (14.1) |
| 6–8 h                                   | 92 (44.9) |
| <6 h                                    | 84 (41.0) |
Table 2b
Changes in frequency of performing self-care activities during the COVID-19 pandemic compared to a similar pre-pandemic time.

| Self-care activity                      | Changes in frequency of engaging in self-care activities n (%) |
|----------------------------------------|-------------------------------------------------------------|
|                                        | Increased significantly | Increased | Stayed the same | Decreased | Decreased Significantly |
| Healthful eating habits                | 13 (6.3)                | 19 (9.3)  | 148 (72.2)      | 18 (8.8)  | 7 (3.4)                |
| Exercise                               | 9 (4.4)                 | 13 (6.3)  | 108 (52.4)      | 31 (15.0) | 45 (21.8)              |
| Self-monitoring of blood glucose       | 21 (10.3)               | 13 (6.4)  | 143 (70.1)      | 17 (8.3)  | 10 (4.9)               |
| Foot care                              | 9 (4.4)                 | 6 (2.9)   | 187 (91.2)      | 3 (1.5)   | 0 (0.0)                |
| Smoking*                               | 3 (9.1)                 | 3 (9.1)   | 19 (57.6)       | 4 (12.1)  | 4 (12.1)               |

* Responses of the 33 participants who reported smoking.

amounts (Table 2a). A large majority of participants (73.7%) were non-adherent to engaging in at least 30 min of physical activity. Around half of the participants were non-adherent to SMGB (47.6%) and foot care (46.6%).

One-in-six (16.0%) participants reported smoking during the past week. When asked about the number of hours spent sitting during a weekday, the average time was 7.8 ± 4.6 h. Finally, before the COVID-19 pandemic, around half of the participants (51.9%) reported sleeping 6–8 h at night while 35.4% reported less than 6 h of sleep, and these figures did not change substantially during the pandemic.

Table 2b illustrates changes in frequency of performing self-care activities during the COVID-19 pandemic compared to a similar pre-pandemic time. Overall, the majority of participants reported that they performed self-care activities at the same frequency before and during the pandemic. Exercise was the self-care activity that saw the most common decline, with over one-third of the participants (36.8%) reporting a decrease in the frequency of exercise. It was followed by SMGB (13.2%), healthy eating habits (12.2%), and foot care (1.5%). On the other hand, 16.7% of participants reported increased frequency of SMGB, and 15.6% and 10.7% reported increased frequency of healthy eating habits and exercise, respectively. Nearly one-quarter (24.2%) of participants who smoked reported a decrease in smoking.

The majority of participants reported high self-efficacy; 93.7% and 68.6% were confident in taking diabetes medication and carrying out self-care activities as prescribed, respectively. Diabetes distress level was low among most of the participants (85.9%), and 10.7% had a moderate level of distress, while 3.4% reported high levels of distress.

The most reported challenges were having regular appointments with the diabetes doctor (30.3% reported ‘challenging’ or ‘somewhat challenging’), receiving a lot of information about COVID-19 from many sources (29.3%), communicating concerns about diabetes management with the health care team (20.1%), and doing regular lab tests (17.6%) (Table 3).

Table 3
Challenges of people with type 2 diabetes in accessing and using diabetes care during the COVID-19 pandemic (N = 206).

| Statements describing access and use of diabetes care | Level of difficulty n (%) |
|-------------------------------------------------------|---------------------------|
|                                                       | Challenging | Somewhat challenging | Not challenging |
| Having regular appointments with the diabetes doctor   | 36 (17.6)   | 26 (12.7)   | 143 (69.8)   |
| Receiving a lot of information about COVID-19 from many sources | 29 (14.4)   | 30 (14.9)   | 142 (70.6)   |
| Communicating concerns about diabetes management with the health care team (doctor, nurse, dietitian, or diabetes educator) | 22 (10.8)   | 19 (9.3)   | 163 (79.9)   |
| Doing regular lab tests                               | 16 (7.8)    | 20 (9.8)    | 168 (82.4)   |
| Obtaining diabetes medicines from the pharmacy         | 9 (4.4)     | 12 (5.9)    | 183 (89.7)   |
| Receiving counseling from the pharmacists about the use of prescribed diabetes treatment | 10 (4.9)    | 10 (4.9)    | 184 (90.2)   |
| Getting a prescription from the doctor                 | 9 (4.4)     | 10 (4.9)    | 186 (90.7)   |
| Obtaining diabetes medical supplies (e.g., insulin syringes or pens, test strips, etc.) | 7 (3.4)     | 10 (4.9)    | 187 (91.7)   |
| Paying for diabetes medicine as prescribed by the doctor | 13 (6.4)    | 2 (1.0)     | 188 (92.6)   |

Table 4
Change in clinical parameters and diabetes treatment of people with type 2 diabetes during COVID-19 pandemic (N = 206).

| Clinical parameters | Mean ± SD Before COVID-19 | During COVID-19 | P     |
|---------------------|---------------------------|-----------------|-------|
| HbA1c (%)           | 8.2 ± 1.9                 | 8.0 ± 1.7       | 0.080 |
| LDL (mg/dL)         | 76.7 ± 31.1               | 74.7 ± 30.0     | 0.264 |
| Total cholesterol (mg/dL) | 151.3 ± 37.4 | 149.4 ± 37.4 | 0.830 |
| Serum creatinine (mg/dL) | 0.9 ± 1.0    | 0.9 ± 1.1       | 0.996 |
| Urinary albumin (mg) | 62.8 ± 146.1              | 73.4 ± 173.7    | 0.077 |
| BMI (kg/m²)         | 31.1 ± 5.9                | 31.0 ± 6.0      | 0.609 |
| Diabetes treatment before COVID-19                       | n (%)                     |                  |
| Combination of OHA/insulin/GLP-1 receptor agonist        | 97 (47.1)                 |                 |
| OHA only          | 83 (40.3)                 |                 |
| Insulin only      | 16 (7.8)                  |                 |
| GLP-1 receptor agonist only                           | 3 (1.5)                  |                 |
| Diet alone        | 1 (0.5)                   |                 |
| Diabetes treatment modification during COVID-19          | n (%)                     |                  |
| No modifications       | 150 (72.8)                |                 |       |
| Treatment modified          | 51 (25.0)                |                 |       |
| Treatment intensified      | 44 (86.3)                |                 |       |
| Treatment de-intensified   | 6 (11.8)                 |                 |       |
| Types of treatment modification |            |                  |       |
| Insulin added/switched to insulin                    | 7 (13.7)                 |                 |       |
| Insulin regimen intensified                   | 28 (54.9)                |                 |       |
| Insulin regimen de-intensified/ discontinued       | 4 (7.8)                  |                 |       |
| OHA added                      | 4 (7.8)                  |                 |       |
| OHA dose decreased/OHA discontinued          | 2 (3.9)                  |                 |       |

*LDL: Low density lipoprotein cholesterol; BMI: Body mass index; OHA: Oral hypoglycemic agent(s); GLP-1: glucagon-like peptide-1.
Table 5

Associations between challenges with and knowledge about diabetes management with changes in self-care activities during the COVID-19 pandemic.

| Changes in frequency of engaging in self-care activities (%) | Healthy eating habits | Exercise | SMBG | Foot care | Smoking |
|-------------------------------------------------------------|----------------------|---------|------|----------|---------|
| Decreased Same Increased | Decreased Same Increased | Decreased Same Increased | Decreased Same Increased | Decreased Same Increased | Decreased Same Increased |
| Number of challenges | | | | | |
| <2 | 10 (7.5) | 101 | 23 (17.2) | .025 | 38 (28.1) | .003 | 15 (11.1) | .067 | 82 | | | |
| ≥ 2 | 13 (20.6) | 41 | 9 (14.3) | .026 | 53 (82.4) | 24 | 6 (9.5) | .067 | 7 (11.1) | .025 | 44 | |
| Items on knowledge about diabetes management rated | | | | | | | | | | | | |
| <2 | 15 (9.0) | 125 | 26 (15.7) | .057 | 56 (33.5) | 19 (11.4) | .091 | 16 (9.6) | .057 | 31 (18.7) | .004 | |
| ≥ 2 | 9 (23.7) | 24 | 5 (13.2) | .003 | 20 (52.6) | 16 | 2 (5.3) | .026 | 3 (7.9) | .003 | 36 (1.2) | |
| ‘insufficient’ | | | | | | | | | | | | |
| <2 | 15 (9.0) | 125 | 26 (15.7) | .057 | 56 (33.5) | 19 (11.4) | .091 | 16 (9.6) | .057 | 31 (18.7) | .004 | |
| ≥ 2 | 9 (23.7) | 24 | 5 (13.2) | .003 | 20 (52.6) | 16 | 2 (5.3) | .026 | 3 (7.9) | .003 | 36 (1.2) | |

4. Discussion

Our study provided broad insight into the everyday management and challenges of diabetes during the COVID-19 pandemic. This information is critical for healthcare providers and patients to adapt their self-management strategies. The most frequently observed modifications were intensification of insulin regimen (54.9%), adding insulin to existing therapy (13.7%), and using dia- betes healthcare services. Participants who reported having two or more items about diabetes management rated ‘insufficient’ items on knowledge about diabetes management were significantly more likely to report decreased adherence to SMBG (p = 0.004) and increased smoking (p = 0.001).
4.1. Limitations

Caution must be exercised with the generalization of study findings due to a non-probabilistic sample from one major hospital. Additionally, recall bias could have occurred when participants were asked to reflect on self-care activities during a similar pre-pandemic time. Finally, we could not determine if changes in treatment during the pandemic were due to the natural progression of diabetes or if they were potentially accelerated during COVID-19.

5. Conclusions

Arabic-speaking people with T2DM showed resilience and appeared to maintain similar self-care activities levels with no deterioration in clinical parameters compared to pre-pandemic.

Funding

This study was funded by an Operational Grant from the University of Sharjah in the UAE [grant number 150316]. The University of Sharjah had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] World Health Organization, Coronavirus disease (COVID-19) pandemic (Internet), 2020. (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/guidelines-quick-checklist-for-dry-cough-body-temperature-symptoms). (Accessed 10 August 2021).

[2] M. Ernesto, B. Raffaella, Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics, Diabetes Metab. Res. Rev. 37 (7) (2020).

[3] Fang L., Karakiulakis G., Roth M., Are patients with hypertension and diabetes at increased risk for COVID-19 infection? Lancet Respir. Med., (Internet), 2020 Apr 1, 8(4), e21. Available from: (http://www.thelancet.com/artic le/s0140-6736(20)31246-6/fulltext). (Accessed 10 August 2021).

[4] M. Alessandro, D.B. Christopher, Z. Minghua, T. Giovanni, Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies, Nutr. Metab. Cardiovasc. Dis. 30 (8) (2020) 1236–1248.

[5] L. Zhou, Z.G. She, X. Cheng, J.J. Qin, X.J. Zhang, J. Cai, et al., Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 diabetes, Cell Metab. 31 (6) (2020) 1068–1077.

[6] A.K. Singh, K. Khanti, Assessment of risk, severity, mortality, glycemic control and anti-diabetic agents in patients with diabetes and COVID-19: a narrative review, Diabetes Res. Clin. Pract. 165 (2020), 108266.

[7] F. Alawadi, E. Abdelgadir, A. Bashier, M. Hassanein, F. Rashid, M. Alsaed, et al., Glycemic control in patients with diabetes across primary and tertiary government health sectors in the Emirates of Dubai, United Arab Emirates: a five-year pattern, Oman Med. J. 34 (1) (2021) 20–25. [https://www.semanticscholar.org/paper/Global-Control-In-Patients-with-Diabetes-across-A.-Alawadi-Abdelgadir/d4d7cfe58ebcbca63d24fbee6bebefc393727bed1].

[8] F. Fisher, D. Hestler, W. Polonsky, L. Strycker, U. Masharani, A. Peters, Diabetes distress in adults with type 1 diabetes: prevalence, incidence and change over time, J. Diabetes Complicat. 30 (6) (2021) 1123.

[9] J.W. Sacre, E. Holmes-Truscott, A. Salim, K.J. Amstey, G.R. Drummond, R.R. Husley, et al., Impact of the COVID-19 pandemic and lockdown restrictions on psychosocial and behavioural outcomes among Australian adults with type 2 diabetes: findings from the PREDICT cohort study, Diabet. Med. 38 (9) (2021).

[10] L. Joensen, K. Madsen, L. Holm, K. Nielsen, M. Rod, A. Petersen, et al., Diabetes and COVID-19: psychosocial consequences of the COVID-19 pandemic in people with diabetes in Denmark, what characterizes people with high levels of COVID-19-related worries? Diabet. Med. 37 (7) (2020) 1146–1154.

[11] M.E. Al-Sofiani, S. Albunyan, A.M. Alguwaiher, R.R. Kalyani, S.H. Golden, A. Alfladda, Determinants of mental health outcomes among people with and without diabetes during the COVID-19 outbreak in the Arab Gulf Region, J. Diabetes 13 (4) (2021) 339–352.

[12] Y.V. Chudasama, C.L. Gillies, F. Zaccardi, B. Coles, M.J. Davies, S. Seidu, et al., Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals, Diabetes Metab. Syndr. 14 (4) (2020) 965.

[13] M. Banerjee, S. Chakrabarty, R. Pal, Diabetes self-management amid COVID-19 pandemic, Diabetes Metab. Syndr. 14 (4) (2020) 351.

[14] S. Sacchetti, J. Bradley, C. England, A. Searle, A. Whitmarsh, Exploring support needs of people living with diabetes during the coronavirus COVID-19 pandemic: insights from a UK survey, BMJ Open Diabetes Res. Care 9 (1) (2021), e002162.

[15] D. Alromaihi, N. Alamuddin, S. George, Sustainable diabetes care services during COVID-19 pandemic, Diabetes Res. Clin. Pract. 166 (2020).

[16] H. Alzubaidi, K. M. Namara, C. Chapman, V. Stevenson, J. Merritt, Medicine-taking experiences and associated factors: comparison between Arabic-speaking and Caucasian English-speaking patients with Type 2 diabetes, Diabet. Med. 32 (12) (2015) 1625–1633.

[17] H. Alzubaidi, K.M. Namara, C. Browning, Time to question diabetes self-management support for Arabic-speaking migrants: exploring a new model of care, Diabet. Med. 34 (3) (2017).

[18] R. Hamoudi, N. Sahab Sharif-Azkan, F. Sahab Sharif-Azkan, S. Abuamuna, H. Aljaibeij, J. Taneera, et al., Prediabetes and diabetes prevalence and risk factors comparison between ethnic groups in the United Arab Emirates, Sci. Rep. 9 (1) (2019) 1–7.

[19] World Health Organization. United Arab Emirates Situation: Coronavirus Disease (COVID-19) (Internet), 2019. (https://covid19.who.int/region/emro/country/ae). (Accessed 10 August 2021).

[20] D.J. Toobert, S.E. Hampson, R.E. Glasgow, Development of a summary of diabetes self-care activities measure: Results from 7 studies and a revised scale, Diabetes Care 23 (7) (2000) 943–950.

[21] M. Grabia, R. Markiewicz-Zukowska, A. Pucison-Jakubik, J. Bielecka, P. Nowakowski, K. Gromkowska-Kopcha, et al., The nutritional and health effects of the COVID-19 pandemic on patients with diabetes mellitus, Nutrients 12 (10) (2020) 1–15.

[22] L. Fisher, R.E. Glasgow, J.T. Mullan, M.M. Skaff, W.H. Polonsky, Development of a brief diabetes distress screening instrument, Ann. Fam. Med. 6 (3) (2008) 246–252.

[23] M. Mohseni, S. Ahmadi, S. Azami Aghdash, H.M. Infahani, A. Moosavi, M. Fardid, et al., Challenges of routine diabetes care during COVID-19 era: a systematic search and narrative review, Prim Care Diabetes (2021).

[24] D. Brsan, S. Aeblicher Perrone, M. Castelluga Perrolini, F. Chappuis, P. Chopard, D.M. Haller, et al., Beyond the virus: ensuring continuity of care for people with diabetes during COVID-19, Prim Care Diabetes 15 (1) (2021) 16–17.

[25] H. Farhane, M. Motrane, F.-E. Anabir, A. Motrane, S.N. Abedl, N. Harich, COVID-19 pandemic: effects of national lockdown on the state of health of patients with type 2 diabetes mellitus in a Moroccan population, Prim Care Diabetes 15 (5) (2021) 772.

[26] H. Utri, B.V. Dogru, The effect of the COVID-19 pandemic on self-management in patients with type 2 diabetes, Prim Care Diabetes (2021).

[27] Al-Dwaikat TN, Rababah JA, Al-Hammouti MM, Chleb Ewe, Social Support, Self-Efficacy, and Psychological Wellbeing of Adults with Type 2 Diabetes, (Internet), 2020, 43(4) 288–97 (https://doi.org/10.17177/1913945920911010). (Accessed 30 August 2021).

[28] J. Yao, H. Wang, X. Yin, J. Xin, X. Guo, Q. Sun, The association between self-efficacy and self-management behaviors among Chinese patients with type 2 diabetes, PloS One 14 (11) (2019).

[29] R. Aljadad, Y. AlRabta, B. Bolkli, I. Sales, M. Alwahabi, O. Almohammed, et al., The Impact of COVID-19 on essential medicines and personal protective equipment availability and prices in Saudi Arabia, Healthcare 9 (3) (2021).

[30] M.S.H. Sojan, R. Tantim, M.S. Islam, M.Z. Ferdous, M.A.R. Apu, M.M. Musifque, et al., COVID-19-specific diabetes worries amongst diabetic patients: the role of social support and other co-variates, Prim Care Diabetes 15 (5) (2021) 778.

[31] H.F. Jelinek, W.M. Osman, A.H. Khandoker, K. Khalaf, S. Lee, W. Almahmeed, et al., Clinical profiles, comorbidities and complications of type 2 diabetes mellitus in patients from United Arab Emirates, BMJ Open Diabetes Res. Care 5 (1) (2017).

[32] E. Al-Ozairi, M.K. Jallo, K. Hafidh, D.M. Alhajeri, T. Ashour, E.F.N. Mahmoud, et al., Prevalence of cardiovascular and renal co-morbidities in patients with type 2 diabetes in the Gulf, a cross-sectional observational study, Diabetes Ther. 12 (4) (2021) 1193–1207.